Caution: snapshot figures are a legacy stub. Lisata's equity was restructured in the September 17, 2026 Marea stock deal and $225M Series C placement; legacy holders own about 2.39% and the as-converted equity value is roughly $450M. Discard the market cap and fully diluted cap shown on this page.
What they do
Lisata Therapeutics, Inc. (together with its subsidiaries, the “Company”) is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other serious diseases.
Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.
Share structure
Common
9.0M
Pre-funded warrants
0.0M
Options
1.5M
RSUs
0.0M
Warrants
0.0M
Converts
0.0M
Conv preferred
0.0M
ESPP reserve
0.0M
FDSO
10.5M
Cap table as of 2026-06-30.
On September 17, 2026 Lisata closed a stock deal with Marea Therapeutics alongside a $225M Series C placement. Legacy public holders were diluted to about 2.39% of the combined equity. The share counts, market cap and fully diluted cap on this page are the legacy Lisata stub quote and do not reflect the post-deal capital structure; on an as-converted basis the equity is worth roughly $450M. Treat every valuation figure on this page as stale until the post-deal share counts are filed and the row is rebuilt.
Price history
Loading LSTA daily closes…
Loading price history…
Next catalyst
MAR001 · Est. Nov 15, 2027 · quarter midpoint · guided in 11 mo
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships SBP: worldwide royalty-bearing license to patent rights and know-how for certepetide. Qilu Pharmaceutical (Greater China exclusive license, up to $200M milestones + 10-15% royalties): agreement terminated effective January 23, 2026; Qilu completed enrollment in the Phase 2 CEND1-202 study in first-line mPDAC. Kuva Labs license/collaboration (Nov 2024): terminated; related merger agreement (March 2026) also terminated
Status note Investigational iRGD peptide from the CendR Platform leveraging the C-end rule active transport mechanism to address tumor stroma. Subject of multiple Phase 1/2 trials including the Phase 2 ASCEND trial (with SoC gemcitabine/nab-paclitaxel) and the completed Phase 2a BOLSTER trial; Phase 3 readiness activities in mPDAC (CMC) delayed per the filing.
Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.